Saxena 1999 100 mg.
Methods | As for Saxena 1999 25 mg | |
Participants | — | |
Interventions | — | |
Outcomes | — | |
Notes | — | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Adequate sequence generation? | Low risk | Probably done |
Allocation concealment? | Unclear risk | Unclear from publications |
Blinding? | High risk | Study was single‐blinded because of the prominent colour of the drug and the difficulty in manufacturing a proper placebo |
Completeness of follow‐up | Unclear risk | Unclear from publications |